On December 21, 2021, the first special representative lawsuit of the service center will be executed, and 52037 Kangmei Pharmaceutical investors will receive about 2.459 billion yuan in the form of cash, debt-to-equity swap, trust income rights, etc. The reporter telephoned an individual investor in Kangmei Pharmaceutical Industry in Beijing that night, saying that after deducting the loss caused by the decline in the market risk itself, his reasonable compensation of 17000 yuan had been received yesterday. (Securities Times website)
康美案部分个人投资者赔偿款已到账
The compensation of some individual investors in the Kangmei case has been received.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.